Cereno Scientific announced strengthening of intellectual property rights (IPR) for drug candidate CS1 in the major market Japan. The patent is part of the third patent family which now has protection in Russia as well as Japan. It adds to the growing IPR portfolio for CS1 covering almost all global markets. The patent granted in Japan is part of Cereno's third patent family associated with drug candidate CS1 and is titled ‘Delayed release pharmaceutical formulations comprising valproic acid and uses thereof’. Drug candidate CS1 is currently undergoing a Phase II study for the rare disease pulmonary arterial hypertension (PAH) following investigational new drug (IND) acceptance from US FDA in September 2021. The aim of the study is to confirm CS1's safety, tolerability and efficacy in patients with PAH. It will be conducted at up to nine different clinical centers in USA with 30 participating patients.